GSK大中华区副总裁齐欣离任

Group 1 - GSK's business is divided into three main segments: specialty pharmaceuticals, vaccines, and general pharmaceuticals, with a total revenue of £15.502 billion (approximately $20.157 billion) in the first half of the year, representing a 5% year-on-year growth [2] - The revenue contributions from the three segments are as follows: £6.260 billion ($8.141 billion, +16%), £4.186 billion ($5.443 billion, +1%), and £5.056 billion ($6.573 billion, -3%), indicating pressure on growth in the Chinese market due to competition and policy factors [2] - GSK's R&D investment in the first half of the year was £3.486 billion (approximately $4.532 billion), a 22% year-on-year increase [3] Group 2 - In July, GSK entered into a collaboration with Hengrui Medicine to co-develop up to 12 innovative drugs, with an initial payment of $500 million and a potential total value of approximately $12 billion, which is expected to bring more innovative results to the Chinese market [3] - GSK has undergone several personnel adjustments this year, including the establishment of a Chief Operating Officer position and the integration of emerging markets and Greater China into a new international region [3] - DCH Auriga, the new employer of Cecilia Qi, has a history dating back to the 1850s and provides comprehensive market management services for medical and healthcare products across various Asian countries [4]